Kymera Therapeutics Launches New $500M At-The-Market Equity Offering Program

summarizeSummary

Kymera Therapeutics has established a new At-The-Market (ATM) equity offering program to sell up to $500 million of common stock, providing significant capital flexibility but also potential dilution.

check_boxKey Events

• New $500 Million ATM Program Established

  Kymera Therapeutics has entered into a sales agreement to offer and sell up to $500,000,000 of its common stock through an At-The-Market (ATM) program. This program was announced concurrently with an 8-K filing on the same date.

• Potential Share Dilution

  If the entire $500 million is sold at the assumed price of $91.01 per share (as of February 24, 2026), approximately 5,493,901 new shares could be issued, representing a potential dilution of about 6.76% based on current outstanding shares.

• Use of Proceeds

  The net proceeds from the offering are intended to fund research and clinical development of current or additional pipeline candidates, and for general working capital and corporate purposes.

• Replaces Prior ATM Program

  This new $500 million ATM program replaces a previous $300 million ATM program established in October 2024, which has now terminated.

auto_awesomeAnalysis

Kymera Therapeutics has launched a new At-The-Market (ATM) equity offering program, allowing it to sell up to $500 million of common stock from time to time. This program, detailed in this prospectus supplement, follows the concurrent 8-K announcement of its establishment. The company intends to use the net proceeds for research and clinical development of pipeline candidates, as well as for general corporate purposes. This new program replaces a previously terminated $300 million ATM program from October 2024. While the company reported a robust cash position of $1.6 billion extending its runway into 2029, this new ATM provides substantial additional capital flexibility but also represents potential future dilution for existing shareholders.